WASHINGTON, DC—Adding the PCSK9 inhibitor alirocumab (Praluent; Sanofi/Regeneron) to high-intensity statin therapy enhances coronary plaque regression and stabilization when started early after an ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — In a new study, subcutaneous biweekly alirocumab, added to high-intensity statin therapy, resulted ...
A new study found severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was associated with the rapid growth of plaque in the coronary arteries and an increased risk of cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback